Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q3 2024 · 10-Q
Revenue$0.00$0.00−100.0% vs Q3 2023 Net Income-$6.78M-$6.78MN/M vs Q3 2023 EPS Diluted-$3.94-$3.94N/M vs Q3 2023 Operating Income-$5,062,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$2,742,000N/M ended Sep 30, 2024 · filed Nov 13, 2024 · 44 d after period end